{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:50:27Z","timestamp":1790610627626,"version":"4.1.0"},"reference-count":49,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The liver is supplied by a dual blood flow system consisting of the portal vein and hepatic artery. Imaging techniques for diagnosing hepatocellular carcinoma (HCC) have been developed along with blood flow imaging, which visualizes the amount of arterial and portal blood flow. The diagnosis of HCC differentiation is important for early-stage liver cancer screening and determination of treatment strategies. Dynamic computed tomography\/magnetic resonance imaging (MRI) includes blood flow imaging and MRI with contrast-enhanced ultrasound and liver-specific contrast agents are used in combination. In addition, unlike the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1), which is the standard for determining treatment efficacy for solid tumors in general, tumor necrosis is generally considered a treatment effect in HCC, and the modified RECIST and Liver Cancer Direct Effectiveness Criteria (RECICL) are widely used. Familiarity with the definitions, criteria, and potential challenges of the mRECIST and RECICL is essential for their effective application in clinical practice. This review integrates the latest advancements in systemic treatments and imaging techniques, including the role of LI-RADS and updates on molecular-targeted therapies such as regorafenib, supported by some systematic review and meta-analysis.<\/jats:p>","DOI":"10.3390\/cancers17010101","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:00:37Z","timestamp":1735628437000},"page":"101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiological Assessment and Therapeutic Evaluation in Hepatocellular Carcinoma: Differentiation and Treatment Response with Japanese Guidelines"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-4912","authenticated-orcid":false,"given":"Masakatsu","family":"Tsurusaki","sequence":"first","affiliation":[{"name":"Department of Radiology, Kansai Medical University Medical Center, Moriguchi 570-8503, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-1623","authenticated-orcid":false,"given":"Keitaro","family":"Sofue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kobe University Graduate School of Medicine, Kobe 650-0017, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kobe University Graduate School of Medicine, Kobe 650-0017, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Tanigawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kansai Medical University, Hirakata 573-1010, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical Practice Guidelines for Hepatocellular Carcinoma 2021 version (5th JSH-HCC guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmri.25345","article-title":"Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"45","author":"Duncan","year":"2017","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1007\/s00330-019-06294-6","article-title":"The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi -detector computed tomography in detecting hepatocellular carcinoma: A meta-analysis of eight prospective studies","volume":"29","author":"Li","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00535-015-1097-5","article-title":"Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: A multicenter phase III study","volume":"51","author":"Tsurusaki","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/jhep.2000.9113","article-title":"Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading","volume":"32","author":"Imai","year":"2000","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.11101840","article-title":"Imaging study of early hepatocellular carcinoma: Usefulness of gadoxetic acid-enhanced MR imaging","volume":"261","author":"Sano","year":"2011","journal-title":"Radiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1148\/radiol.2020192275","article-title":"Radiologic- pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: A multicenter study","volume":"296","author":"Joo","year":"2020","journal-title":"Radiology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00261-011-9685-1","article-title":"Hepatocelluar nodules in liver cirrhosis: Hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis","volume":"36","author":"Matsui","year":"2011","journal-title":"Abdom. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2214\/AJR.16.17711","article-title":"Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI: A systematic review and meta-analysis","volume":"209","author":"Suh","year":"2017","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/hepr.13746","article-title":"Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)","volume":"52","author":"Kudo","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","article-title":"Response evaluation of gastrointestinal stromal tumors","volume":"13","author":"Choi","year":"2008","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1148\/radiol.2512081403","article-title":"High-grade soft-tissue sarcomas: Tumor response assessment pilot study to assess the correlation between radiology","volume":"251","author":"Stacchiotti","year":"2009","journal-title":"Radiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1872-034X.2010.00674.x","article-title":"Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)","volume":"40","author":"Kudo","year":"2010","journal-title":"Hepatol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1007\/s00535-014-0936-0","article-title":"Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma","volume":"49","author":"Arizumi","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vincenzi, B., Di Maio, M., Silletta, M., D\u2019Onofrio, L., Spoto, C., Piccirillo, M.C., Daniele, G., Comito, F., Maci, E., and Bronte, G. (2015). Prognostic relevance of objective response according to the EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133488"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_20","unstructured":"American College of Radiology (2024, December 28). Liver Imaging Reporting and Data System Version. Available online: https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/LI-RADS\/LIRADS_2017_Core.pdf."},{"key":"ref_21","unstructured":"American College of Radiology (2024, December 28). Liver Imaging Reporting and Data System (LI-RADS) v2018 ACR.org: ACR. Available online: https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-2018-Core.pdf?la=en."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Aslam, A., Chernyak, V., Miller, F.H., Bashir, M., Do, R., Sirlin, C., Lewandowski, R.J., Kim, C.Y., Kielar, A.Z., and Kambadakone, A.R. (2024). CT\/MRI LI-RADS 2024 Update: Treatment Response Assessment. Radiology, 313.","DOI":"10.1148\/radiol.232408"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mendiratta-Lala, M., Masch, W.R., Shampain, K., Zhang, A., Jo, A.S., Moorman, S., Aslam, A., Maturen, K.E., and Davenport, M.S. (2020). MRI assessment of hepatocellular carcinoma after local-regional therapy: A comprehensive review. Radiol. Imaging Cancer, 2.","DOI":"10.1148\/rycan.2020190024"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4254\/wjh.v12.i10.738","article-title":"Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions","volume":"12","author":"Aslam","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmri.28659","article-title":"Updates on LI-RADS treatment response criteria for hepatocellular carcinoma: Focusing on MRI","volume":"57","author":"Patel","year":"2023","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/SLA.0000000000001384","article-title":"Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: Analysis of 501 consecutively treated patients","volume":"262","author":"Agopian","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/lt.25673","article-title":"Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria after thermal ablation for hepatocellular carcinoma","volume":"26","author":"Cools","year":"2020","journal-title":"Liver Transpl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1148\/radiol.2019191581","article-title":"The LI-RADS version 2018 MRI treatment response algorithm: Evaluation of ablated hepatocellular carcinoma","volume":"294","author":"Chaudhry","year":"2020","journal-title":"Radiology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1148\/radiol.2019182135","article-title":"LI-RADS treatment response algorithm: Performance and diagnostic accuracy","volume":"292","author":"Shropshire","year":"2019","journal-title":"Radiology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, J., Li, H., Zheng, T., Jiang, H., Li, M., and Song, B. (2020). Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. Ann. Transl. Med., 8.","DOI":"10.21037\/atm.2020.03.120"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.diii.2022.06.007","article-title":"Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response","volume":"103","author":"Abdelrahman","year":"2022","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.22747","article-title":"Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres","volume":"49","author":"Riaz","year":"2009","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ijrobp.2021.10.006","article-title":"LI-RADS Treatment Response Algorithm: Performance and diagnostic accuracy with radiologic-pathologic explant correlation in patients with SBRT-treated hepatocellular carcinoma","volume":"112","author":"Aslam","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_39","first-page":"2379","article-title":"Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: A systematic review and meta-analysis","volume":"13","author":"Facciorusso","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Facciorusso, A., Abd El Aziz, M.A., and Sacco, R. (2019). Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12010036"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Abou-Alfa, G.K., Lau, G., Kudo, M., Chan, S.L., Kelley, R.K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.K., Van Dao, T., and De Toni, E.N. (2022). Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2100070"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-21-3135","article-title":"Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies","volume":"28","author":"Kudo","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLI.0b013e3182199bb5","article-title":"Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST)","volume":"47","author":"Jiang","year":"2012","journal-title":"Investig. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/0284185117732805","article-title":"Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: Comparison with mRECIST in longitudinal follow-up","volume":"59","author":"Kaufmann","year":"2018","journal-title":"Acta Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jhep.2014.06.008","article-title":"OATP1B3 expression is strongly associated with Wnt\/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma","volume":"61","author":"Ueno","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hepr.12911","article-title":"Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of beta-catenin and hepatocyte nuclear factor 4alpha in hepatocellular carcinoma","volume":"48","author":"Kitao","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000518048","article-title":"Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1\/PD-L1 monotherapy for unresectable hepatocellular carcinoma","volume":"10","author":"Aoki","year":"2021","journal-title":"Liver Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:55Z","timestamp":1760115475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010101"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010101","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}